Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
https://smallcaps.com.au/immuron-products-found-neutralise-covid-19-during-in-vitro-research/
Filter by Year:
- Immuron (ASX:IMC) develops research agreement
- Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
- Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
- Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment
- Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
